Uncategorized
Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock
Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock
The FDA in February slapped Moderna’s vaccine with a refusal-to-file letter—though the agency backtracked a few days later and accepted a revised submission for review. An advisory committee in June unanimously backed mFLUVISA’s approval. Read More